Halozyme Therapeutics Inc has appointed Darren Snellgrove as chief financial officer, effective 8 June 2026, to lead financial operations and strategy. With 30 years of financial, strategic and operational experience in the biopharmaceutical and medtech sectors, Mr Snellgrove most recently led investor relations at Johnson & Johnson Inc.
Previously, he was CFO of Johnson & Johnson's Pharmaceuticals sector, where he played a central role in major portfolio investments, restructuring initiatives and business development. He also held other senior finance roles at J&J across pharmaceutical R&D, innovation and mergers and acquisitions. Mr Snellgrove holds an MBA from Villanova University, US.
Halozyme Therapeutics announced the appointment on 30 April 2026.
Copyright 2026 Evernow Publishing Ltd.